Savara Added to Nasdaq Biotechnology Index

AUSTIN, TX--(Marketwired - December 18, 2017) - Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI), effective prior to the U.S. market open today, December 18, 2017.

"2017 has been transformative for Savara and our addition to the NBI caps a year of notable milestones which has created significant value for our investors," stated Rob Neville, Chief Executive Officer of Savara. "Over the past year, we have successfully transitioned to the public market and raised approximately $100 million, moved both of our lead assets, Molgradex and AeroVanc, into Phase 3 development and expanded Molgradex development into nontuberculous mycobacteria (NTM) infection."

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked semi-annually in May and November. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index Fund (IBB), which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.

About Savara
Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara's pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for pulmonary alveolar proteinosis, or PAP, and in preparation for Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection; AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in Cystic Fibrosis; and, Aironite, an inhaled sodium nitrite for heart failure with preserved ejection fraction, or HFpEF, in Phase 2 development. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)